Psoriatic Arthritis | Disease Landscape and Forecast | G7 | 2020

A series of launches are expected to impact the increasingly dynamic psoriatic arthritis (PsA) therapy market over the next 10 years and challenge the dominance of the TNF inhibitors; the impact of these launches will be strengthened by the increasing acceptance of biosimilars as alternatives to more-expensive branded therapies and the novel mechanisms of action that are becoming available. IL-17 and IL-23 inhibitors, in particular, are poised to capture substantial sales and, with the diagnosis and drug-treatment rate anticipated to remain relatively steady, could threaten the sales of current therapies, especially the IL-12/23 therapy ustekinumab. Targeted synthetic DMARDs, particularly JAK inhibitors, will fulfill the need for orally dosed therapies and increasingly capture early-line patient share.

Questions Answered

• What impact will current and emerging biosimilars have on the PsA therapy market in the coming years? How will physicians in different markets react to these less-expensive therapies?
• How will newer agents, especially those offering an alternative to the market-leading TNF inhibitors, change the PsA therapy market? What is the physician perception of these therapies?
• What emerging therapies do dermatologists and rheumatologists consider the most promising for PsA? What novel mechanisms of action are considered good clinical targets for this disease?
• What unmet needs remain to be treated in PsA? Will emerging therapies fulfill these needs, and will they be competitive with biosimilars and entrenched branded therapies?

Content Highlights

Geographies: United States, EU5, Japan.

Primary research: 24 country-specific interviews with thought-leading dermatologists and rheumatologists supported by survey data collected for this and other DRG research.

Epidemiology: Number of PsA patients by country, including diagnosed and drug-treated populations.

Forecast: 10-year, annualized, drug-level sales and patient share of key PsA therapies to 2029, segmented by brands / biosimilars.

Emerging therapies: Phase III/PR: 5 drugs; Phase II: 2 drugs.

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.